Astria Therapeutics Inc.

# Signal Note: Perceptive Advisors Initiates $84.9M Position in ATXS Perceptive's substantial entry into Astria suggests conviction in the company's lead program, AT-527 (a nucleotide polymerase inhibitor for RSV), ahead of anticipated Phase 2b data expected in 2024. Edelman's track record of backing clinical-stage assets with meaningful efficacy readouts makes this a credible endorsement, though RSV antivirals face a competitive landscape with GSK and Merck programs in late-stage development. The timing and position size warrant monitoring for upcoming catalysts and potential strategic partnerships.